VectivBio

VectivBio is a Switzerland-based biotechnology company that researches and develops novel therapeutics for the treatment of rare diseases.

Business Model:

Revenue: $0

Employees: 11-50

Detailed VectivBio Information

VectivBio was acquired by Ironwood Pharmaceuticals.
The acquisition happend on 2023-05-22.
Details of the transaction were not public

Geographic Data

VectivBio headquarters map

Address: Aeschenvorstadt 36

City: Basel

State: basel-city

Zip: 4051

Country: CH

Financial Info

Stage:

post ipo equity

Raised Last:

$125M

Raised Total:

$399M

Metrics

4,979,492Website Global Rank

1,894Website Monthly Traffic

Twitter Followers

Description

VectivBio is a Switzerland-based biotechnology company that researches and develops novel therapeutics for the treatment of rare diseases.

Contact Phone:

Contact Email:

VectivBio went public on 4/8/2021 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
4/8/2021

IPO Valuation:
$578M

Ticker Symbol:
VECT

IPO Price:
$17/share

Amount Raised:
$128M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
10/2022 Post-IPO Equity 11 $125M Cowen Healthcare Investments
Driehaus Capital Management
Eventide
Forbion Capital Partners
Frazier Life Sciences
Marshall Wace
OrbiMed
Surveyor Capital
TCG Crossover
Venrock Healthcare Capital Partners
Vivo Capital
4/2021 IPO $127.5M
6/2022 Private Placement $20M
6/2022 Post-IPO Equity $0 Forbion Capital Partners
Forbion Capital Partners
6/2022 Post-IPO Equity $34M
1/2020 Series A 7 $35M Versant Ventures
Tekla Capital Management
OrbiMed
Novo Holdings
Inserm Transfert Initiative
Cowen Healthcare Investments
Bpifrance
10/2020 Equity 10 $110M Cowen Healthcare Investments
Novo Holdings
OrbiMed
Surveyor Capital
Eventide
Cormorant Capital
Bpifrance
Versant Ventures
Inserm Transfert Initiative
Tekla Capital Management
10/2022 Post-IPO Equity $0 Vivo Capital
Venrock Healthcare Capital Partners
TCG Crossover
Surveyor Capital
OrbiMed
Marshall Wace
Frazier Life Sciences
Forbion Capital Partners
Eventide
Driehaus Capital Management
Cowen Healthcare Investments
Cowen Healthcare Investments
Vivo Capital
Venrock Healthcare Capital Partners
TCG Crossover
Surveyor Capital
OrbiMed
Marshall Wace
Frazier Life Sciences
Forbion Capital Partners
Eventide
Driehaus Capital Management
Cowen Healthcare Investments
Cowen Healthcare Investments
3/2022 Post-IPO Debt $0 Kreos Capital
Kreos Capital
6/2022 Post-IPO Equity 1 $54M Forbion Capital Partners
Forbion Capital Partners
3/2022 Post-IPO Debt 1 $75M Kreos Capital
Kreos Capital
Announced Date Name Price
8/2021 Comet Therapeutics

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research